Key result
In children with severe acute viral myocarditis, immunomodulative therapy significantly improved ejection fraction by 39.4% but did not result in a statistically significant difference in overall clinical outcomes compared to anticongestive therapy alone (p>0.05).
Why the study?
Does immunomodulative therapy improve outcomes in children with severe and acute viral myocarditis?
Cohort (n=14)
No
Does immunomodulative therapy improve outcomes in children with severe and acute viral myocarditis?
Immunomodulative therapy combined with anticongestive therapy may lead to successful outcomes in children with severe acute viral myocarditis.
Myocarditis is defined, clinically and pathologically, as inflammation of the heart muscle. The autoimmune phase is belived to play a major role and the use immunosuppressive agents may be useful in containing myocyte destruction. Aims was to systematically review the impact of Immunomodulative therapy on the outcame of severe and acute myocarditis in children. We retrospectively studied all the children admitted to University Children s Hospital with an acute viral myocarditis (AVM) from 2003-2008y. Patients were included if they had 1.severe and acute heart failure, 2 left ventricular dysfunction assessed by echocardiography, 3. a recent history of viralillness and 4. absens of personal or familial history of cardiomyopthy. Fourteen patient (37%) had severe and acute myocaditys. Seven patients were treated with immunomodulative therapy and anticongestive therapy (group I). Other seven patients were treated with anticongestive therapi only (group II). We comparred the use of antikongestiv therapy alone, with a combination of immunomodulative. Such studies have documented succeful outcome of AVM with immunomodulative trearment.
No takes yet. Share an insight, caveat, or question.
Šulović et al. (2007) conducted a cohort in Severe acute viral myocarditis (n=14). Immunomodulative therapy (IVIG and/or prednisolone) vs. Anticongestive therapy alone was evaluated on Completely cured clinical outcome (p=>0.05). In children with severe acute viral myocarditis, immunomodulative therapy significantly improved ejection fraction by 39.4% but did not result in a statistically significant difference in overall clinical outcomes compared to anticongestive therapy alone (p>0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: